Business Description
Stayble Therapeutics AB
ISIN : SE0013513652
Share Class Description:
FRA:4K4: Ordinary SharesTotal Employee Number:
2Compare
Compare
Traded in other countries / regions
STABL.Sweden4K4.Germany IPO Date
2020-03-12Description
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.32 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 59.2 | |||||
3-Year EPS without NRI Growth Rate | 58.9 | |||||
3-Year FCF Growth Rate | 59.8 | |||||
3-Year Book Growth Rate | -53.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 54.65 | |||||
9-Day RSI | 56.78 | |||||
14-Day RSI | 57.27 | |||||
3-1 Month Momentum % | 53.74 | |||||
6-1 Month Momentum % | 9.18 | |||||
12-1 Month Momentum % | -35.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 1.43 | |||||
Cash Ratio | 0.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.4 | |||||
Shareholder Yield % | -35.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -159.24 | |||||
ROA % | -125.25 | |||||
ROIC % | -201.57 | |||||
3-Year ROIIC % | -1317.85 | |||||
ROCE % | -140.8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 12.81 | |||||
EV-to-EBIT | -1.11 | |||||
EV-to-EBITDA | -1.11 | |||||
EV-to-FCF | -2 | |||||
Earnings Yield (Greenblatt) % | -90.09 | |||||
FCF Yield % | -44.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Stayble Therapeutics AB Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.016 | ||
| Beta | 4.4102 | ||
| 3-Year Sharpe Ratio | 0.6 | ||
| 3-Year Sortino Ratio | 2.83 | ||
| Volatility % | 639.42 | ||
| 14-Day RSI | 57.27 | ||
| 14-Day ATR (€) | 0.001058 | ||
| 20-Day SMA (€) | 0.02284 | ||
| 12-1 Month Momentum % | -35.43 | ||
| 52-Week Range (€) | 0.0024 - 0.0392 | ||
| Shares Outstanding (Mil) | 64.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Stayble Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Stayble Therapeutics AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-19 | In 134 days | ||
| Second quarter earnings results for 2026 | 2026-08-20 | In 43 days | ||
| General meeting for 2026 | 2026-06-24 | 0.02 (+0.00%) | ||
| Annual report for 2025 | 2026-05-27 | 0.02 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-21 | 0.02 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-25 | 0.02 (+3.25%) | ||
| Third quarter earnings results for 2025 | 2025-11-19 | 0.02 (-9.88%) | ||
| Second quarter earnings results for 2025 | 2025-08-20 | 0.03 (+2.89%) | ||
| General meeting for 2025 | 2025-06-05 13:00 | 0.04 (+6.12%) | ||
| First quarter earnings results for 2025 | 2025-05-21 | 0.03 (+6.23%) |
Show
Entries
Stayble Therapeutics AB Frequently Asked Questions
What is Stayble Therapeutics AB(FRA:4K4)'s stock price today?
The current price of FRA:4K4 is €0.02. The 52 week high of FRA:4K4 is €0.04 and 52 week low is €0.00.
When is next earnings date of Stayble Therapeutics AB(FRA:4K4)?
The next earnings date of Stayble Therapeutics AB(FRA:4K4) is 2026-08-20 Est..
Does Stayble Therapeutics AB(FRA:4K4) pay dividends? If so, how much?
Stayble Therapeutics AB(FRA:4K4) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Stayble Therapeutics AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers